Results 211 to 220 of about 759,031 (383)
Some Considerations Regarding the Problem of Multidimensional Utility [PDF]
The concept of 'utility' is often used in ambiguous ways in economics, from having substantive psychological connotations to being a formal placeholder representing a person's preferences.
Martin Binder
core
NEUROMUSCULAR DISEASE. 1990. (Series: Current Trends in Neurosciences). Edited by M. Adachi and J.H. Sher. Published by Igaku Shoin. 348 pages. $128.00 Cdn. [PDF]
, 1991 Michael H. Brooke
openalex +1 more source
Understanding Mechanisms of Whole Brain and Regional Grey Matter Atrophy in Children With MOGAD
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To investigate the mechanisms driving whole brain and regional grey matter (GM) volume changes along with their clinical correlates in paediatric myelin oligodendrocyte glycoprotein antibody (MOG‐Ab)–associated disease (MOGAD). Methods One‐hundred‐nine paediatric MOGAD patients from two UK centres underwent MRI at attack nadir and ...
Ermelinda De Meo +14 more
wiley +1 more source
In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock +8 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li +10 more
wiley +1 more source
A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester +4 more
wiley +1 more source
Converging levels of analysis in the cognitive neuroscience of visual attention [PDF]
, 1998 John S. Duncan
openalex +1 more source
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji +9 more
wiley +1 more source